ConvaTec Group - CNVVY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$12.83
▲ +0.1225 (0.96%)

This chart shows the closing price for CNVVY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ConvaTec Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNVVY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNVVY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.83.

This chart shows the closing price for CNVVY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in ConvaTec Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/15/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/26/2024UBS GroupUpgradeStrong-Buy
9/7/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
9/5/2023The Goldman Sachs GroupInitiated CoverageBuy
8/10/2023Berenberg BankBoost TargetGBX 280 ➝ GBX 290
8/9/2023Morgan StanleyBoost TargetGBX 250 ➝ GBX 260
8/7/2023Stifel NicolausUpgradeHold ➝ Buy
8/3/2023BarclaysBoost TargetGBX 300 ➝ GBX 310
8/3/2023JPMorgan Chase & Co.Boost TargetGBX 290 ➝ GBX 320
7/7/2023HSBCUpgradeReduce ➝ Hold
6/8/2023JPMorgan Chase & Co.Lower TargetGBX 305 ➝ GBX 290
6/1/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/23/2023Credit Suisse GroupBoost TargetGBX 220 ➝ GBX 225
5/19/2023BarclaysBoost TargetGBX 295 ➝ GBX 300
3/10/2023JPMorgan Chase & Co.Boost TargetGBX 281 ➝ GBX 305
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
1/10/2023BarclaysBoost TargetGBX 290 ➝ GBX 295
11/22/2022BarclaysLower TargetGBX 295 ➝ GBX 290
11/22/2022Jefferies Financial GroupInitiated CoverageBuy
11/18/2022JPMorgan Chase & Co.Boost TargetGBX 275 ➝ GBX 381
11/18/2022Liberum CapitalInitiated CoverageBuy
11/14/2022Morgan StanleyBoost TargetGBX 227 ➝ GBX 235
11/11/2022BarclaysBoost TargetGBX 290 ➝ GBX 295
11/11/2022Credit Suisse GroupBoost TargetGBX 225 ➝ GBX 230
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
10/10/2022BarclaysLower TargetGBX 295 ➝ GBX 290
8/22/2022Peel HuntDowngradeBuy
8/9/2022Credit Suisse GroupBoost TargetGBX 200 ➝ GBX 225
6/27/2022JPMorgan Chase & Co.Boost TargetGBX 230 ➝ GBX 255
5/31/2022BarclaysLower TargetGBX 290 ➝ GBX 285
5/19/2022Credit Suisse GroupBoost TargetGBX 195 ➝ GBX 200
5/18/2022Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform
3/17/2022Berenberg BankInitiated CoverageBuy
3/11/2022Credit Suisse GroupLower TargetGBX 210 ➝ GBX 195
3/1/2022BarclaysBoost TargetGBX 290 ➝ GBX 295
1/21/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ OverweightGBX 278 ➝ GBX 256
11/24/2021Royal Bank of CanadaReiterated RatingUnderperform
11/2/2021UBS GroupReiterated RatingBuy
11/1/2021BarclaysReiterated RatingOverweight
11/1/2021JPMorgan Chase & Co.Reiterated RatingOverweight
11/1/2021Credit Suisse GroupReiterated RatingUnderperform
9/9/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
8/9/2021Royal Bank of CanadaDowngradeSector Perform ➝ Underperform
8/2/2021Credit Suisse GroupReiterated RatingUnderperform
8/2/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/2/2021Stifel NicolausDowngradeBuy ➝ Hold
6/1/2021Royal Bank of CanadaReiterated RatingSector Perform
5/10/2021BarclaysReiterated RatingOverweight
5/6/2021Peel HuntUpgradeBuy
5/4/2021Credit Suisse GroupReiterated RatingUnderperform
4/30/2021BarclaysReiterated RatingOverweight
4/30/2021JPMorgan Chase & Co.Reiterated RatingNeutral
3/8/2021JPMorgan Chase & Co.Reiterated RatingNeutral
1/19/2021BarclaysReiterated RatingOverweight
1/4/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
12/9/2020Morgan StanleyReiterated RatingEqual Weight
11/18/2020Morgan StanleyReiterated RatingEqual Weight
10/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
10/29/2020BarclaysReiterated RatingOverweight
9/29/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
9/23/2020BarclaysUpgradeEqual Weight ➝ Overweight
9/23/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
8/7/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
8/7/2020Credit Suisse GroupReiterated RatingUnderperform
7/2/2020Morgan StanleyReiterated RatingEqual Weight
7/1/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
6/26/2020Peel HuntDowngradeBuy
5/18/2020BarclaysReiterated RatingEqual Weight
4/1/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
1/20/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/9/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
11/12/2019Sanford C. BernsteinInitiated CoverageUnderperform
(Data available from 7/15/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/17/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ConvaTec Group logo
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $12.83
Low: $12.77
High: $12.97

50 Day Range

MA: $12.76
Low: $11.90
High: $13.56

52 Week Range

Now: $12.83
Low: $9.90
High: $15.40

Volume

5,600 shs

Average Volume

35,127 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ConvaTec Group?

The following equities research analysts have issued reports on ConvaTec Group in the last twelve months: Barclays PLC, Berenberg Bank, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for CNVVY.

What is the current price target for ConvaTec Group?

0 Wall Street analysts have set twelve-month price targets for ConvaTec Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ConvaTec Group in the next year.
View the latest price targets for CNVVY.

What is the current consensus analyst rating for ConvaTec Group?

ConvaTec Group currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNVVY will outperform the market and that investors should add to their positions of ConvaTec Group.
View the latest ratings for CNVVY.

What other companies compete with ConvaTec Group?

How do I contact ConvaTec Group's investor relations team?

ConvaTec Group's physical mailing address is 23 Forbury Road, Reading, Berkshire RG1 3JH. The company's listed phone number is 441189528100. The official website for ConvaTec Group is www.convatecgroup.com. Learn More about contacing ConvaTec Group investor relations.